Zoetis : Receives European Commission Marketing Authorization for APOQUEL® chewable tablets (oclacitinib) for the treatment of itch and inflammation in allergic dogs

A Convenient Solution to Rapidly and Safely Stop the Cycle of Pruritus in Allergic Dogs and Clinical Signs of Atopic Dermatitis in Dogs

ZAVENTEM, BELGIUM, January 10, 2022 - Zoetis announced that the European Commission (EC) has granted the marketing authorization for Apoquel^® chewable tablets (oclacitinib) for dogs for the treatment of clinical manifestations of pruritus associated with allergic dermatitis in dogs and the treatment of clinical manifestations of atopic dermatitis in dogs at least 12 months of age. Pruritus, or itching, is the most common sign of allergies in dogs. The Veterinary Medicines Directorate (VMD) marketing authorization for Great Britain (GB) was received on November 24^th, 2021.

"The approval of Apoquel chewable tablets in the European Union provides a convenient new treatment choice for dogs that suffer from allergic skin conditions. This treatment affords an opportunity for the damaged skin to heal, while allowing the veterinarian ample time to identify the underlying cause of a dog's allergic disease," said Robert J Polzer, PhD, Executive Vice President and President, Research and Development at Zoetis. "Zoetis is committed to research and development programs that advance the health and quality of life for pets while serving the unmet needs of our veterinary customers in better ways."

Discovered and developed by Zoetis, Apoquel (oclacitinib) is the first Janus kinase (JAK) inhibitor approved for veterinary use that targets the itch and inflammation pathway. And now oclacitinb is available in a tasty chewable (Apoquel chewable), as well as a tablet form (Apoquel) giving owners of dogs with allergic dermatitis a choice of treatment form to decrease their dog's itch. Apoquel chewable provides convenient and easily palatable fast-acting relief from itching and improves inflammation for the estimated 150 million dogs in Europe that suffer from short- and long-term allergic skin conditions.

"Atopic dermatitis is one of the most common allergies in dogs, affecting approximately 10 per cent of the dog population. Itching caused by an allergic skin disease can impact the quality of life for both the dog and its owner unless they are controlled with effective management. Apoquel chewable tablets, now offers a new convenient and palatable solution for the dog owners with dogs that need short or long-term treatment," said Jamie Brannan, President International Operations.

Mike McFarland, DVM, Chief Medical Officer at Zoetis added: "Many dog owners have trouble administering tablets to their pet. When a dog requires long-term, daily treatment for their skin allergies it can be a real problem. Apoquel chewable provides a treatment option that dogs readily accept. This builds on the strong bond that unites dog owners with their pets, as they provide the treatment and itch relief their dog needs in a palatable tablet."

Apoquel chewable tablets will be available by prescription only. Apoquel chewable tablets, dosed at 0.4 to 0.6 mg/kg, are administered orally, twice daily for up to 14 days, and then administered once daily for maintenance therapy.

Zoetis plans to make Apoquel chewable tablets available to veterinarians during 2022. As the latest addition to the company's diverse portfolio of companion animal dermatology products (Apoquel, Cytopoint), this approval signifies an important milestone for the leading animal health company.

About APOQUEL

APOQUEL chewable is uniquely targeted to stop the itch and inflammation associated with allergic skin disease. It is a selective inhibitor of the Janus kinase (JAK) 1 enzyme, a protein that is integral to the signaling pathway that results in itching and inflammation. Its novel mechanism of action on the JAK enzyme is specifically designed to target the pruritogenic and proinflammatory pathways involved in the itch cycle, allowing control of the signs of allergic disease.

About Zoetis

As the world's leading animal health company, we are driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After nearly 70 years innovating ways to predict, prevent, detect, and treat animal illness, we continue to stand by those raising and caring for animals worldwide - from livestock farmers to veterinarians and pet owners. The company's leading portfolio and pipeline of medicines, vaccines, diagnostics, and technologies make a difference in over 100 countries. In 2020, we generated revenue of $6.7 billion with ~11,300 employees. For more information, visit www.zoetis.com.

DISCLOSURE NOTICES

Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to business plans or prospects and expectations regarding products. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, including in the sections thereof captioned "Forward-Looking Statements and Factors That May Affect Future Results" and "Item 1A. Risk Factors," in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.